HC Wainwright Has Optimistic Outlook of DWTX Q2 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of Dogwood Therapeutics in a research note issued to investors on Tuesday, May 19th. HC Wainwright analyst S. Lee now expects that the company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.32). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.14 EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.60) EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.

Separately, Weiss Ratings cut Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Stock Performance

Shares of DWTX opened at $1.84 on Thursday. Dogwood Therapeutics has a 52 week low of $1.28 and a 52 week high of $9.50. The stock has a market capitalization of $61.88 million, a price-to-earnings ratio of -0.17 and a beta of 1.68. The stock has a fifty day moving average of $2.02 and a 200-day moving average of $3.52.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.